EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sierra Oncology's enterprise value is $1,074.42 Mil.
Sierra Oncology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 was $-102.30 Mil. Therefore, Sierra Oncology's EV-to-EBITDA for today is -10.50.
The historical rank and industry rank for Sierra Oncology's EV-to-EBITDA or its related term are showing as below:
SRRA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.5 Med: -2.06 Max: -0.03
Current: -10.5
During the past 9 years, the highest EV-to-EBITDA of Sierra Oncology was -0.03. The lowest was -10.50. And the median was -2.06.
SRRA's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 10.055
vs SRRA: -10.50
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Sierra Oncology EV-to-EBITDA Historical Data
The historical data trend for Sierra Oncology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sierra Oncology's EV-to-EBITDA
For the Biotechnology subindustry, Sierra Oncology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sierra Oncology's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sierra Oncology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sierra Oncology's EV-to-EBITDA falls into.
Sierra Oncology's current Enterprise Value is $1,074.42 Mil.
Sierra Oncology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-102.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sierra Oncology (NAS:SRRA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sierra Oncology's PE Ratio for today is calculated as:
Sierra Oncology's share price for today is $54.99.
Sierra Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.770.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Sierra Oncology's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Sierra Oncology (Sierra Oncology) Business Description
Sierra Oncology Inc is a clinical-stage drug development company. It focuses on the research, development, and commercialization of DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. In addition, it also engaged in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in the preclinical development stage.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SRRA has been successfully added to your 